Does oestrogen lead to improved survival in women with non-small cell lung cancer?

Ostberg J
March 2004
Thorax;Mar2004, Vol. 59 Issue 3, p241
Academic Journal
No abstract available.


Related Articles

  • Preoperative chemotherapy did not significantly increase OS in NSCLC.  // Hem/Onc Today;4/25/2010, Vol. 11 Issue 8, p22 

    The article discusses results from the randomized phase-3 Southwest Oncology Group Trial S9900, which revealed that preoperative chemotherapy for operable early-stage non-small cell lung cancer does not lead to improved five-year overall survival (OS) or mortality.

  • Updates in Non-Small Cell Lung Cancer. Walker, Suzanne // Clinical Journal of Oncology Nursing;Aug2008, Vol. 12 Issue 4, p587 

    Lung cancer is the leading cause of cancer death in both men and women. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing more than 80% of lung cancer diagnoses. Five-year survival remains at 15%, but new strategies for prevention, early detection, and...

  • Non-Small Cell Lung Cancer: New Hope for a Chronic Illness. Tyson, Leslie B. // Oncology Nursing Forum;Sep2007, Vol. 34 Issue 5, p963 

    The article proposes everyday interventions that nurses can use to help control tobacco use to prevent lung cancer. It notes that control of tobacco use, new information on the molecular biology of lung cancer and modern developments in treatment can lead to curtailment of lung cancer and...

  • Higher radiation dose does not help lung cancer patients live longer.  // Biomedical Market Newsletter;10/10/2011, Vol. 21, p260 

    The article reports that a 74 gray (Gy) dose of radiation does not improve survival of nonsmall cell lung cancer patients, according to a study's interim review presented at the 53rd Annual Conference of the American Society for Radiation Oncology on October 3, 2011.

  • New data suggests new lung cancer drug, Tarceva, extends patient survival.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p9 

    Discusses the phase III study of the efficacy of Tarceva, an investigational lung cancer drug, in improving overall survival of cancer patients. Response rate of cancer patients to the drug; Advancement in treating patients with relapsed non-small cell lung cancer; Diagnosis of lung cancer.

  • Challenges in NSCLC molecular testing. Korpanty, Grzegorz; Leighl, Natasha B. // Oncology Exchange;Nov2012, Vol. 11 Issue 4, p8 

    The authors comment on the challenges faced by medical institutions in treating non-small cell lung cancer (NSCLC) in Canada. They say lung cancer remains the leading cause of cancer-related mortality in both women and men in the region, with a 5-year survival rate of only 18%. They offer...

  • Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Xinghua Cheng; Haiquan Chen // OncoTargets & Therapy;2014, Vol. 7, p1689 

    Lung cancer, mostly nonsmall cell lung cancer, continues to be the leading cause of cancer-related death worldwide. With the development of tyrosine kinase inhibitors that selectively target lung cancer-related epidermal growth factor receptor mutations, management of advanced nonsmall cell lung...

  • Higher mortality from non-small cell lung cancer reported in subjects treated with oestrogen and progestin.  // Thorax;Mar2010, Vol. 65 Issue 3, p200 

    The article discusses the results of the study which reveal the increased prevalence of morality and incidence among non-small cell lung cancer patients treated with hormone therapy involving both oestrogen and progestin.

  • Preoperative chemotherapy showed a trend toward improved five-year DFS. Adams, Stacey L.; Haigh, Christen; Harris, Jason // Hem/Onc Today;9/25/2009, Vol. 10 Issue 18, p42 

    The article discusses a research in Spain which has found that preoperative chemotherapy has led to improved five-year disease-free survival in patients with non-small cell lung cancer.

  • Motesanib extended survival in NSCLC.  // Hem/Onc Today;7/10/2014, Vol. 15 Issue 13, p10 

    The article discusses a phase 3 study, published in the "Annals of Oncology," which revealed that adding motesanib to carboplatin and paclitaxel has improved the overall survival of nonsquamous non-small cell lung cancer (NSCLC) patients.


Read the Article


Sign out of this library

Other Topics